文献速递神经免疫

EDSS、T25FW与NHPT作为复发缓解型多发性硬化临床试验结局的比较

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-08-25

该研究基于CombiRx试验(1008例复发缓解型多发性硬化患者)数据,比较EDSS与T25FW、NHPT作为残疾结局指标的表现。结果显示EDSS恶化与改善频率相当,T25FW改善率低,且Kaplan-Meier法会夸大恶化估计。提示EDSS作为标准结局存在问题,T25FW可能更实用。

要点

  • EDSS恶化与改善频率相当,提示其作为结局指标可能不够可靠。
  • T25FW改善率低(<10%),可能更稳定反映真实残疾变化。
  • Kaplan-Meier法较保守分析可高估恶化2.6-5.1倍。

核心结论

  • EDSS作为RRMS试验标准残疾结局存在担忧,T25FW可能是更有用的指标。

研究设计与样本

  • 基于CombiRx试验(NCT00211887)的1008例RRMS患者数据,比较EDSS与T25FW、NHPT。

主要发现

  • 确认恶化事件中持续恶化比例较低,24个月阳性预测值EDSS 0.73、T25FW 0.73、NHPT 0.8。
  • EDSS恶化频率与改善相当,T25FW改善率<10%。
  • Kaplan-Meier法对3个月确认恶化(至36个月)的估计较保守方法高:EDSS 2.6倍、T25FW 2.9倍、NHPT 5.1倍。

临床怎么用

  • 在RRMS试验设计中应考虑T25FW等更稳定指标,并谨慎解读Kaplan-Meier估计。

局限性

  • 分析基于单一RCT数据集,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Clinical trials in relapsing-remitting multiple sclerosis (RRMS) usually use the Expanded Disability Status Scale (EDSS) as their primary disability outcome measure, while the more recently developed outcomes timed 25-ft walk (T25FW) and 9-hole peg test (NHPT) may be more useful and patient relevant. The objective of this work was to compare the EDSS to the T25FW and NHPT in a large RRMS randomized controlled trial (RCT) dataset. METHODS: We used the dataset from Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx) (clinicaltrials.gov identifier NCT00211887), a large phase 3 RCT, to compare the EDSS to the alternative outcomes T25FW and NHPT. We investigated disability worsening vs similarly defined improvement, unconfirmed vs confirmed and sustained disability change, and the presentation methods cumulative Kaplan-Meier survival curves vs cross-sectional disability worsening. RESULTS: CombiRx included 1,008 participants. A comparison of confirmed and sustained worsening events showed that, throughout the trial, there were substantially fewer sustained than confirmed events, with a positive predictive value of confirmed for sustained worsening at 24 months of 0.73 for the EDSS, 0.73 for the T25FW, and 0.8 for the NHPT. More concerning were the findings that worsening on the EDSS occurred as frequently as similarly defined improvement throughout the 3 years of follow-up and that improvement rates increased in parallel with worsening rates. The T25FW showed low improvement rates of <10% throughout the trial. We also found that Kaplan-Meier survival analysis, the standard presentation and analysis method in modern RRMS trials, yields exaggerated estimates of disability worsening. With the Kaplan-Meier method, the proportion of patients with worsening events steadily increases until it reaches several-fold the number of events seen with more conservative analysis methods. For 3-month confirmed disability worsening up to 36 months, the Kaplan-Meier method yields 2.6-fold higher estimates for the EDSS, 2.9-fold higher estimates for the T25FW, and 5.1-fold higher estimates for the NHPT compared to a more conservative presentation of the same data. DISCUSSION: Our analyses raise concerns about using the EDSS as the standard disability outcome in RRMS trials and suggest that the T25FW may be a more useful measure. These findings are relevant for the design and critical appraisal of RCTs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Koch MW, Mostert JP, Wolinsky JS, et al. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Neurology. 2021. PMID: 34433679. doi:10.1212/WNL.0000000000012690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。